[go: up one dir, main page]

WO2008129529A3 - Cannabinoid for the treatment of neuronal damage in diabetic patients - Google Patents

Cannabinoid for the treatment of neuronal damage in diabetic patients Download PDF

Info

Publication number
WO2008129529A3
WO2008129529A3 PCT/IL2008/000477 IL2008000477W WO2008129529A3 WO 2008129529 A3 WO2008129529 A3 WO 2008129529A3 IL 2008000477 W IL2008000477 W IL 2008000477W WO 2008129529 A3 WO2008129529 A3 WO 2008129529A3
Authority
WO
WIPO (PCT)
Prior art keywords
neuronal damage
cannabinoid
treatment
diabetic patients
tetrahydrocannabinol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2008/000477
Other languages
French (fr)
Other versions
WO2008129529A2 (en
Inventor
Elliot Berry
Raphael Mechoulam
Yosefa Avraham
Yossi Dagon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of WO2008129529A2 publication Critical patent/WO2008129529A2/en
Publication of WO2008129529A3 publication Critical patent/WO2008129529A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides for the use of an effective amount of at least one cannabinoid selected from the group consisting of HU-210 and Tetrahydrocannabinol (THC) for the manufacture of a pharmaceutical composition for alleviating neuronal damage due to hyperglycemia, or for treating neuronal damage in a diabetic subject, wherein HU-210 is the (+)-1,1-dimethylheptyl analog of 7-hydroxy-delta-6- tetrahydrocannabinol of the formula (I).
PCT/IL2008/000477 2007-04-19 2008-04-06 Cannabinoid for the treatment of neuronal damage in diabetic patients Ceased WO2008129529A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91272007P 2007-04-19 2007-04-19
US60/912,720 2007-04-19
IL190531A IL190531A0 (en) 2008-03-31 2008-03-31 Cannabinoid for the treatment of neuronal damage in diabetic patients
IL190531 2008-03-31

Publications (2)

Publication Number Publication Date
WO2008129529A2 WO2008129529A2 (en) 2008-10-30
WO2008129529A3 true WO2008129529A3 (en) 2008-12-24

Family

ID=39764920

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2008/000477 Ceased WO2008129529A2 (en) 2007-04-19 2008-04-06 Cannabinoid for the treatment of neuronal damage in diabetic patients

Country Status (2)

Country Link
IL (1) IL190531A0 (en)
WO (1) WO2008129529A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006226A1 (en) * 2006-07-14 2008-01-17 Wine, Harvey Transdermal formulations of synthetic cannabinoids and nano colloidal silica

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008006226A1 (en) * 2006-07-14 2008-01-17 Wine, Harvey Transdermal formulations of synthetic cannabinoids and nano colloidal silica

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CAMERON NORMAN ET AL: "The cannabinoid agonist, WIN555212-2, corrects nerve and vascular dysfunction in diabetic rats.", DIABETES, vol. 52, no. Supplement 1, 2003, & 63RD SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION; NEW ORLEANS, LA, USA; JUNE 13-17, 2003, pages A4 - A5, XP009106950, ISSN: 0012-1797 *
DAGON ET AL: "The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells", NEUROBIOLOGY OF DISEASE, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 27, no. 2, 26 July 2007 (2007-07-26), pages 174 - 181, XP022169195, ISSN: 0969-9961 *
DOGRUL A ET AL: "Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 368, no. 1, 16 September 2004 (2004-09-16), pages 82 - 86, XP004549487, ISSN: 0304-3940 *
LI XINGUANG ET AL: "Examination of the immunosuppressive effect of DELTA9-tetrahydrocannabinol in streptozotocin-induced autoimmune diabetes", INTERNATIONAL IMMUNOPHARMACOLOGY, vol. 1, no. 4, April 2001 (2001-04-01), pages 699 - 712, XP002499429, ISSN: 1567-5769 *
MARSICANO GIOVANNI ET AL: "Neuroprotective properties of cannabinoids against oxidative stress: Role of the cannabinoid receptor CB1", JOURNAL OF NEUROCHEMISTRY, vol. 80, no. 3, February 2002 (2002-02-01), pages 448 - 456, XP002499428, ISSN: 0022-3042 *
SCOTT DAVID A ET AL: "Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat", PAIN, vol. 109, no. 1-2, May 2004 (2004-05-01), pages 124 - 131, XP002499430, ISSN: 0304-3959 *
ULUGOL A ET AL: "The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 371, no. 2-3, 23 November 2004 (2004-11-23), pages 167 - 170, XP004618552, ISSN: 0304-3940 *
WILLIAMS JOVAN ET AL: "Decreased basal endogenous opioid levels in diabetic rodents: Effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 584, no. 1, April 2008 (2008-04-01), pages 78 - 86, XP022561529, ISSN: 0014-2999 *

Also Published As

Publication number Publication date
WO2008129529A2 (en) 2008-10-30
IL190531A0 (en) 2009-02-11

Similar Documents

Publication Publication Date Title
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2008054639A3 (en) Use of a catechin or polyphenol to treat ocular diseases and infection
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
BRPI0611717A2 (en) compound, pharmaceutical composition and use of the compound
PH12013501790B1 (en) Use of dpp iv inhibitors
NZ589228A (en) Combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) for the treatment of a brain tumour
WO2009001362A3 (en) Herbal compositions for the treatment of diabetes and/or conditions associated therewith
MX2010001696A (en) Pharmaceutical composition comprising a glucopyranosyl-substitute d benzene derivative.
WO2008108958A3 (en) Benzimidazole derivatives and methods of use thereof
PH12013500919B1 (en) Vasoprotective and cardioprotective antidiabetic therapy
NZ597704A (en) Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy
MX2009009417A (en) Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain.
BRPI0519803A2 (en) methods for purifying trans - (-) - delta9-tetrahydrocannabinol and trans - (+) - delta9-tetrahydrocannabinol
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2009098072A3 (en) Composition for the treatment of oxidative stress
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
WO2007109201A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2010028132A3 (en) Novel choline cocrystal of epalrestat
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
BRPI0716985A2 (en) NUTRITIONAL COMPOSITION, USE OF THE SAME, AND NUTRITIONAL SUPPLEMENT FOR THE TREATMENT OF PATIENTS SUFFERING FROM FOOD ALLERGIES
CA2915751C (en) Compositions comprising at least one polymethoxyflavone, flavonoid, liminoid, and/or tocotrienol useful in combination therapies for treating diabetes
WO2010011926A3 (en) A novel betaine cocrystal of epalrestat

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08720069

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08720069

Country of ref document: EP

Kind code of ref document: A2